INTRODUCTION
Adrenomedullin (ADM), recently identified from extract of phaeochromocytoma tissue, has structural homology to calcitonin gene-related peptide and amylin [l]. Intravenous administration of ADM to rats elicits a strong, long-lasting hypotensive effect [2] . Considerable mRNA expression has been recognized in large organs such as the heart, kidney and lung [3] . Moreover, immunoreactive ADM has been detected in human plasma [3] . Recent studies suggest that vascular smooth muscle cells possess specific ADM receptors that are functionally coupled to adenylate cyclase [4, 51. These findings suggest the possibility that ADM is a peptide that participates in the regulation of the cardiovascular system. In fact, the plasma levels of ADM are reported to be increased in patients with essential hypertension, chronic renal failure and heart failure [6-81. However, little is known about the pathophysiological significance of ADM in patients with acute myocardial infarction (AMI).
Our objective was to determine the behaviour of ADM in AMI. To that end, we measured plasma levels of ADM in the right atrium, pulmonary artery and aorta by specific radioimmunoassay in patients with AMI. We examined ADM in relation to haemodynamic and other parameters and humoral factors in the acute and late phase of AMI.
METHODS
We studied 36 Japanese patients with AM1 (28 men, 8 women) aged 39 to 84 years (mean age & SD, 59 f 13 years). The diagnosis of AM1 was based on two of the three criteria: (i) typical ischaemic chest pain lasting longer than 30 min, (ii) electrocardiographic ST-segment elevation of 0.1 mV in two contiguous leads, (iii) elevation of serum total creatine kinase and its MB isoenzyme to at least twice the upper limit of normal. We excluded from study patients with a history of congestive heart failure, chronic atrial tachyarrythmias, previous myocardial infarction, chronic obstructive lung disease or chronic renal failure. The average time from onset of symptoms to admission was 4.2 f 2.6 h (mean groups: those with no signs and symptoms of cardiac failure (Killip class I) (Group I) and those with developing signs of dysfunction or cardiac decompensation (Killip class 11, 111 and IV) (Group 11) [9] . Before admission, 12 of the patients with AM1 had been taking calcium antagonists. Three of the patients with AM1 had been on angiotensin-converting enzyme inhibitors alone. All patients were treated with calcium antagonists and nitrates after admission. Diuretics were used in 13 patients with congestive heart failure. None of them was treated with B-blocker.
We also studied 12 age-and sex-matched control subjects who were electively admitted to our hospital with a chief complaint of chest pain. The 10 men and 2 women were aged 46 to 76years (mean age & SD, 61 9 years). All subjects electively underwent cardiac catheterization and their findings were normal. None of them had myocardial infarction, hypertension, cardiac hypertrophy or other cardiovascular diseases. None of them was receiving therapy at the time of the study.
Informed consent was obtained from each patient and/or family in the early phase of AM1 and again later from each patient. This study protocol was in agreement with the guidelines of the committee on ethics of Tohsei National Hospital and National Cardiovascular Center.
Right-sided cardiac catheterization, coronary arteriography and left ventriculography were performed in all patients as soon as patients were admitted. Right atrial, pulmonary arterial and pulmonary capillary wedge pressures were measured by a Swan-Ganz thermodilution catheter (Model 93A-431H-7.5Fr, Baxter Healthcare Co., CA, U.S.A.). Cardiac output was calculated by the thermodilution method [lo] . Twenty-eight of the 36 patients underwent direct percutaneous transluminal coronary angioplasty, while four patients underwent percutaneous transluminal coronary recanalization via the intracoronary infusion of prourokinase. The remaining four patients were treated conservatively because the infarct-related coronary arteries were patent at the time of coronary arteriography. A second cardiac catheterization was performed on 1 day after admission to see whether or not infarctrelated coronary artery was patent. Infarct-related coronary arteries were patent in 33 of 36 patients. Four weeks after admission, 33 patients underwent another cardiac catheterization. At that time, the infarct-related coronary artery was patent in 30 patients. Left ventricular ejection fraction was calculated using the area-length method.
Blood samples were obtained from the right atrium, pulmonary main trunk and ascending aorta before the pressure recording was made. After blood sampling, arteriography and left ventriculography were routinely performed. Blood samples were collected on admission, 1 day after admission and 4 weeks after the treatment of AMI. The 7 ml blood samples were added to chilled tubes containing disodium EDTA (1 mg/ml) and aprotinin (500 kallikrein-inhibiting units/ml) and were centrifuged immediately at 4°C. The plasma samples were stored at -80°C until they were extracted before radioimmunoassay. For radioimmunoassay, Sep-Pak C18 cartridges (Waters of Millipore, Milford, U.S.A.) were prewashed sequentially with 5 ml each of chloroform, methanol, 50% acetonitrile containing 0.1% trifluoroacetic acid, 0.1% trifluoroacetic acid and saline solution. A 2ml sample of plasma was acidified with 24 p1 of 1 mol/l hydrochloric acid and diluted with 2ml of saline solution, then loaded onto a Sep-Pak C18 cartridge. After being washed with 5 ml each of saline solution, and 0.1% trifluoroacetic acid, the absorbed materials were eluted with 4 ml of 50% acetonitrile containing 0.1% trifluoroacetic acid. The eluate was then lyophilized. The lyophilized material was dissolved in radioimmunoassay buffer, and the clear solution was submitted to radioimmunoassay. The radioimmunoassay for ADM was described previously [6] . Delta ADM was calculated as plasma levels of ADM in the pulmonary artery minus plasma levels of ADM in the aorta. Plasma levels of atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP) were measured by Shiono RIA ANP and Shiono RIA BNP assay kit (Shionogi Co., Osaka, Japan) as reported previously [ 111.
Comparisons between two groups were evaluated with the x2 test, the paired Student's t-test, or the unpaired Student's t-test if appropriate. Comparisons among multiple groups were performed with the one-way analysis of variance followed by Scheffe's test, the one-way analysis of variance for repeated measures or the two-way analysis of variance for repeated measures, as appropriate. Correlation coefficients were calculated by linear regression analysis. A level of P < 0.05 was accepted as statistically significant.
RESULTS
Baseline characteristics of the two groups are shown in Table 1 . There were no differences in age, sex, time between onset and admission, site of myocardial infarction and treatment in the acute phase. Of the 36 patients, 3 patients died during the study protocol. Two patients in group 11 died on the second or third day because of cardiogenic shock, and one patient in group I died in the third week due to the complication of pneumonia.
Haemodynamic parameters and plasma levels of ANP and BNP in the right atrium among the three groups are shown in Table 2 . Plasma levels of ANP and BNP were significantly higher in group I1 than in the control group. In addition, there was a significant difference in plasma levels of BNP between group I and group 11. In group 11, mean pulmonary capillary wedge pressure and mean pulmonary arterial pressure significantly decreased on 1 day after admission (20 f 2 to 11 f 2 mmHg, 29 f 2 to 20 f 1 mmHg, respectively, P < 0.05).
Patients with AM1 were divided into three groups according to the time from onset to admission. Plasma levels of ADM in the right atrium increased within 3 h after the onset of symptoms and remained elevated at least 9 h after the onset of AM1 (AMI; 1.5-3 h: 10.7f 1.7 pmol/l; 3-6 h: 10.9k0.9 pmol/l; 6-9 h: 11.8 f 1.5 pmol/l; control; 5.2f0.3 pmolfl, P<O.Ol). As seen in Fig. 1, plasma levels of ADM were significantly higher on admission in the patients with AM1 (10.6 f 1.0 pmolfl, P<O.Ol) than in the control group. Furthermore, plasma levels of ADM were higher in group I1 than in group I on admission. Plasma levels of ADM remained elevated the next day and decreased at 4 weeks in patients with AMI. There were no significant differences in the plasma levels of ADM between admission and the day after admission in the patients with or without successful reperfusion (10.8f 1.2 to 11.Of 1.3 pmolfl with reperfusion, 8.4 f 0.8 to 8.7 f 0.7 pmolfl without reperfusion; not significant). Plasma levels of ADM in the aorta tended to be lower than those in the right atrium or pulmonary artery in patients with AM1 and the control group, but the differences were not statistically significant (Fig. 2) . However, the delta ADM in the AM1 groups during protocol was higher than that in the control group. Plasma levels of ADM on admission were significantly correlated with plasma levels of ANP (r = 0.442; P < 0.05) and BNP (r = 0.470; P < 0.05) in group 11. On the other hand, plasma levels of ADM did not correlate with plasma levels of ANP (r=0.379; not significant) or BNP ( r = 0.089; not significant) in group I. There were no significant correlations between plasma levels of ADM and haemodynamic parameters on admission in either group of patients with AMI. There were no significant correlations between plasma levels of ADM and other humoral factors or haemodynamic parameters on the day after admission and at 4 weeks in either group of patients with AMI.
DISCUSSION
In the present study, we demonstrated that plasma levels of ADM were increased rapidly in the very early phase of AMI. Furthermore, plasma levels of ADM in patients with congestive heart failure were significantly higher than those in patients without that complication and correlated positively with plasma levels of ANP and BNP.
In AMI, plasma adrenaline and noradrenaline levels increase within 2 h after onset of symptoms [ 121. Previous studies reported a correlation between plasma levels of ADM and plasma levels of noradrenaline in patients with essential hypertension, chronic renal failure and congestive heart failure [7, 81. According to the report of the genomic structure of human ADM gene, the 5'4anking region contains binding sites for activator protein-2 and CAMP-regulated enhance elements, suggesting that expression of the ADM gene may be subject to the activity of protein kinase C and cAMP levels [ 131. Because noradrenaline activates protein kinase C and phospholipase C through the al-receptor, increased plasma noradrenaline levels may affect the gene expression of ADM through the al-receptor. Furthermore, plasma noradrenaline levels were significantly greater in AM1 with congestive heart failure than in uncomplicated AM1 [14] . This finding suggested that an activated sympathetic nervous system may also be related to increased plasma levels of ADM in AM1 complicated by congestive heart failure.
Activation of the renin-angiotensin system occurs early in patients with AM1 [15] . Angiotensin I1 was a potent stimulant of ADM gene expression among vasoactive peptides [16] . Thus, activation of the renin-angiotensin system in AM1 may be involved in increased plasma levels of ADM. On the other hand, immediate local responses include the accumulation and activation of monocytes and macrophages. These cells then release the acute-phase cytokines, including interleukin la, interleukin-6 and tumour necrosis factor [ 171. Interleukin-6 and tumour necrosis factor are increased within 3 h in AM1 [18, 191 . Sugo et al. [20] reported that cytokines such as tumour necrosis factor and interleukin-la markedly stimulated ADM production in cultured rat vascular smooth muscle cells. Thus, several cytokines and vasoactive substances may be involved in the increased plasma levels of ADM in the acute phase of AMI.
In addition, ANP and BNP correlated with ADM only in patients with AM1 complicated by congestive heart failure. These natriuretic peptides are known to be an indicator of volume expansion [21, 221. Therefore, volume expansion may also have the additive stimulatory effect on ADM production in the early phase of AMI.
Kobayashi et al. [23] have reported positive correlations between ADM and haemodynamic parameters in the early stage of AM1 in a small number of patients. Our data differ somewhat from their study. The absence of these correlations in our study group indicated that in these haemodynamically wellrecovered patients, other factors may influence ADM production and thereby obscure the relationship with haemodynamic parameters.
Nishikimi et al. [24] previously reported that the lung was the partial clearance site of circulating ADM in humans. There are many ADM binding sites in the lungs and hearts in rats, found by using a receptor binding assay technique [25] . In addition, ADM receptor mRNA was highly expressed in the lungs [26] . In the present study, uptake of circulating ADM in the lungs, expressed by the delta ADM, was larger in patients with AM1 than in the control subjects. ADM reduced the lobar arterial pressure of the feline in a dose-dependent manner in vivo [27] . Therefore, ADM may reduce the pulmonary resistance in patients with AM1 as a compensatory mechanism.
Regardless of the reperfusion, there was no significant difference between plasma levels of ADM on admission and those on the following day in our patients with AMI. A previous study found no increase in the plasma levels of ADM in the coronary sinus relative to the aorta in patients with ischaemic heart disease [24] . Therefore, the coronary circulation may not largely affect the circulating ADM levels in the early phase of AMI.
The source of circulating ADM remains unknown. Sugo et al. [28] reported that vascular endothelial cells and vascular smooth muscle cells prominently synthesize and secrete ADM in vitro. Other studies showed that specific receptors for ADM are present in cultured vascular smooth muscle cells and ADM increases intracellular cAMP levels [ 1, 51. Although the exact source of circulating ADM in humans is unknown, these results suggest that the vascular wall may be one of the important production sites of circulating ADM and may participate in the control of vascular tone. The exact source of circulating ADM needs to be studied further.
In the present study, plasma levels of ADM on admission in patients with congestive heart failure were lower than those reported by Cheung et al.
[29] (17.5 pmol/l). Blood samples were obtained at a single time-point in the acute phase. The peak value of plasma levels of ADM occurred 27 h after the onset of AM1 [23] . It is possible that the timing of blood sampling is an important point that may have affected the difference between our study and the study of Cheung et al. [29] . In addition, our radioimmunoassay system is different from theirs. Our specific anti-ADM antibody recognizes the whole ADM[1-521 structure and does not cross-react with smaller fragments of ADM. Indeed, their normal value of ADM is 7.8pmol/l, 1.5 times higher than our normal value of 5.2pmol/l. Thus, higher ADM levels in heart failure in their study may be due to differences in specificity of the anti-ADM antibody used.
Many physiological actions of ADM have been reported. ADM decreases blood pressure, by decreasing total peripheral resistance, and increases urine flow and urinary sodium excretion [2, 30, 311 . Moreover, ADM dilates pulmonary artery and decreases pulmonary vascular resistance [27] . The observed increase of ADM in AM1 may compensate heart failure by decreasing peripheral and pulmonary resistance or increasing urinary sodium and water excretion.
In conclusion, plasma levels of ADM were increased in the early phase of AM1 with or without congestive heart failure and normalized after 1 month. Plasma levels of ADM were especially high in patients with congestive heart failure and correlated with plasma levels of ANP and BNP. Our results suggest that ADM is increased in AM1 and that volume expansion may have the additive effect on ADM production.
